Recent Updates
Recently added Catalysts
ZBIO

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

Tuesday, September 5, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
8.9%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Orelabrutinib
Phase 3 · Multiple Sclerosis (MS) Primary Progressive

Full Press Release Details

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb.
ShareAdd on Google
Tags: ZBIO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 5, 2023

Biotech snapshot

Cash runway
$643M liquidity · $19M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OrelabrutinibPhase 3
Multiple Sclerosis (MS) Primary Progressive →

Catalyst track record

+116%
best trade around ZBIO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ZBIO.

See every catalyst's timing & PoA →